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Abstract: The question of improved relaxivity, and potential efficacy therein, for
a next-generation of magnetic resonance gadolinium chelates with extracellular
distribution and renal excretion, which could also be viewed from the perspective
of dose, is addressed on the basis of historical development, animal experimenta-
tion, and human trials. There was no systematic evaluation that preceded the
choice of 0.1 mmol/kg as the standard dose for human imaging with the gadolin-
ium chelates. In part, this dose was chosen owing to bloodwork abnormalities
seen in phase I and phase II studies. Animal investigations and early clinical trials
demonstrated improved lesion detectability at higher doses in the brain, liver, and
heart. By designing an agent with substantially improved relaxivity, higher en-
hancement equivalent to that provided with the conventional gadolinium agents
at high dose could be achieved, translating to improved diagnosis and, thus, clin-
ical care. Implicit in the development of such high-relaxivity agents would be sta-
bility equivalent to or exceeding that of the currently approved macrocyclic
agents, given current concern regarding dechelation and gadolinium deposition
in the brain, skin, and bone with the linear agents that were initially approved.
Development of such next-generation agents with a substantial improvement
in relaxivity, in comparison with the current group of approved agents, with a
2-fold increase likely achievable, could lead to improved lesion enhancement,
characterization, diagnosis, and, thus, clinical efficacy.
KeyWords: gadolinium, relaxivity, contrast media, magnetic resonance imaging
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T he developmental history of contrast media for magnetic resonance(MR) has spanned more than 30 years.1 It is important to note that
many of the agents that were initially approved for clinical use have now
either been withdrawn or are no longer available. This reflects in part
the difficulty in development of agents for MR and the marked evolu-
tion of the field with the unpredictability therein concerning need for
specific types of contrast media. Three oral contrast agents were approved
in the early years of MR, 1 based on dilution of a conventional gadolinium
(Gd) chelate (developed for intravenous [IV] administration),2 the second
an oral iron preparation,3 and the third a manganese chloride–based agent.4
Timewise, these were the first agents to be discontinued from the market,
with low utilization a major reason. Non–Gd-based agents for IVadminis-
tration were developed for liver imaging, with 3 approved, 3 large iron par-
ticles,5,6 and a manganese-based chelate.7 As with the oral contrast media,
with time, these agentswere discontinued and are no longer clinically avail-
able. Within this latter group, there were concerns about possible toxicity,
and the incidence ofmild immediate allergic type reactionswas higher than
with the Gd chelates. The next agent temporally to leave the clinical market
was the single blood-pool Gd chelate that was eventually approved.8
Although therewas initially great interest in development of blood-poolReceived for publicationNovember 6, 2017; and accepted for publication, after revision,
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                        This paper can be cited using the date of access and the unagents for MR, with time, the market and need for such became quite
limited. This occurred in part because of the technological success of
contrast-enhanced (CE) MR angiography (MRA), which was enabled by
the development of short-echo-time (TE), high-resolution 3-dimensional
(3D) gradient echo imaging techniques, which could be utilized
for imaging the bolus of a conventional extracellular Gd chelate within
both the arterial and venous systems.9 These developments left the 6
conventional, extracellular, renally excreted Gd chelates that had been
approved, together with 2 Gd chelates that have hepatobiliary in addi-
tion to renal excretion (Table 1). These 8 agents, however, fall into 3 dis-
tinct groups by chemical structure and the stability, specifically the
macrocyclic chelates, the linear ionic chelates, and the nonionic linear
chelates (listed in order from highest to lowest stability both in vitro
and in vivo). Owing to the establishment of a causal relationship be-
tween administration of less thermodynamically/kinetically stable Gd
chelates and occurrence of nephrogenic systemic fibrosis (NSF),10–12
and subsequently that of dechelation with deposition of Gd (no longer
bound to the original chelate) in specific areas of the brain,13–17 as well
as in the skin and bone, the attention of the regulatory authorities
worldwide has been attracted, with the European authorities ruling
to leave only the 3 macrocyclic Gd chelates on the clinical market
with a whole-body indication.18 Reflecting upon these developments,
it is important to note that the Gd chelates are critical to medical diag-
nosis today and overall have a very high safety profile.
Chemical synthesis and the ability to evaluate molecules, both in
terms of potential safety and relative to their contrast effect (relaxivity),
is much advanced today in comparison to the 1980s and early 1990s,
when the clinical agents that are available today were conceived. After
the development of that group of agents, the cost in terms of approval
for a new agent dramatically increased.19 This factor, together with the
subsequent consolidation of the diagnostic pharmaceutical industry and
the maturation of the market, led to lower interest in development of
next-generation contrast media. Today, there is renewed interest in this
area, specifically in development for clinical use of high-relaxivity
Gd chelates (with a relaxivity approximately twice that of the agents
currently approved for whole body use)—as indicated by 1 ongoing clin-
ical trial and multiple patent filings, detailed subsequently. This review
provides a background for the development of such agents and overviews
briefly the current status. It advocates what is felt to be a critical new area
of development, with the potential to both substantially improve patient
safety as well as to offer diagnostic possibilities not available with the
current agents. Three major topics are addressed—the question of dose,
imaging technique, and influencing relaxivity. Within the last section, the
relaxivities of the currently approved agents are first considered, followed
in order by a discussion of blood pool, fibrin binding and non–protein
binding, and low- to intermediate-molecular-weight agents (Table 2).
Today, research is focused on this last group, which seems to hold themost
promising candidates for next-generation high-relaxivity Gd chelates.QUESTION OF DOSE
The dose used today for contrast enhancement with the Gd che-
lates is considered on the basis of the developmental history, animal
evaluations, and clinical trials. The reason for this discussion is that
one way the next-generation high-relaxivity Gd chelates could bewww.investigativeradiology.com 1
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TABLE 1. Approved* Gd-Based MR Contrast Agents
Type Chemical Name Generic Name (INN) Trade Name Manufacturer
Macrocyclic Gd-DO3A-butrol Gadobutrol Gadovist/Gadavist Bayer HealthCare
Gd-DOTA Gadoterate meglumine Dotarem Guerbet
Gd-HP-DO3A Gadoteridol ProHance Bracco
Linear ionic Gd-DTPA Gadopentetate dimeglumine Magnevist Bayer HealthCare
Gd-BOPTA Gadobenate dimeglumine MultiHance Bracco
Gd-EOB-DTPA Gadoxetic acid disodium Primovist/Eovist Bayer HealthCare
Linear nonionic Gd-DTPA-BMA Gadodiamide Omniscan GE-Healthcare
Gd-DTPA-BMEA Gadoversetamide OptiMARK Guerbet
* In November 2017, the European Commission adopted the decision of the EuropeanMedicines Agency to suspend the marketing authorizations for intravenous use
for Omniscan, Optimark, and Magnevist and to restrict the use of MultiHance to liver scans only, with EU member states having 2 months to 1 year to implement this
decision.
Gd indicates gadolinium; MR magnetic resonance; INN, International Nonproprietary Names.
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         viewed is for use to achieve an enhancement effect similar to that pos-
sible with high doses of the current agents. The latter (use of high dose)
is limited today, due both to safety concerns as well as cost.
Initial clinical trials with the first agent developed, gadopentetate
dimeglumine, were performed at 0.1 mmol/kg, in part as a result of
laboratory findings in phase I and with no attempt to systematically
study dose efficacy. Phase I with gadopentetate dimeglumine evalu-
ated doses from 0.05 to 0.25 mmol/kg. In this limited evaluation, an
increase in serum iron and bilirubin was noted for subjects receiving
a dose higher than 0.1 mmol/kg, leading to the choice of 0.1 mmol/kg
for subsequent phase II clinical trials. As the patient population evalu-
ated was expanded, an increase in serum iron and bilirubin was also
seen at this dose, although of lower magnitude.20,21 The agent was sub-
sequently reformulated with twice the amount of excess chelate initially
included (0.4 mg/mL).
Two articles published in 199222,23 conclusively demon-
strated improved visualization of brain metastases at doses higher than
0.1 mmol/kg. In both studies, which compared 0.3 with 0.1 mmol/kg,
higher dose enabled visualization of lesions not seen at standard dose.
In the study by Yuh, 46 new lesions were detected in 19 of 27 patients.
In 1994, the overall experience from this multicenter phase III trial of
gadoteridol was published.24 A total of 49 patients were included in
the analysis. Of these, multiple lesions were demonstrated in 5 patients
with high dose who had examinations at standard dose demonstrating
only 1 lesion. Also, 1 or more lesions were demonstrated at high dose
in 2 patients who had a normal examination at standard dose. Imaging
results at high dose would have presumably changed treatment for both
groups. Discussing this in greater detail, if only 1 metastasis is detected,TABLE 2. Advanced Design Gd-based MR Contrast Agents
Type (Subtype)
Blood pool
Protein binding Ga
Ga
BR
Non–protein binding Ga
P7
Fibrin binding EP
Non–protein binding, low to intermediate molecular weight P8
P0
Gd indicates gadolinium; MR, magnetic resonance.
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                        This paper can be cited using the date of access and the unin the appropriate clinical setting and with a favorable lesion location
treatment is by surgical resection. With more than 1 metastasis, and
less than a certain number (variable by site, typically <5-10), stereo-
tactic radiosurgery is performed. With disseminated brain metastases,
whole brain radiation therapy is indicated. It has also been shown that
it is more than just the number of brain metastases that influences
survival. With stereotactic radiosurgery, for example, the presence
of brainstem metastases and high cumulative supratentorial tumor
volume adversely affect patient survival, with detection and assess-
ment therein important to determine patient prognosis.25
The 2 studies cited in the previous paragraph, published in 1992,
as well as that published in 1994 were all performed using an injection
of 0.1 mmol/kg followed 30 minutes later by a supplemental injection
of 0.2 mmol/kg. It was established that the observed results were not
a result of delayed enhancement by observing the time course of en-
hancement between the 2 injections. However, a more difficult study
to perform, comparing dose in the same patient with brain metastatic
disease but on 2 different examinations (separated by more than 24 hours
and less than 7 days, with no intervening therapy), was subsequently
performed to validate these results (Fig. 1).26 In that study, with
15 patients, 40 metastatic brain lesions were detected using a dose
of 0.3 mmol/kg, with only 33 seen on the examination with 0.1 mmol/kg.
Region of interest analysis demonstrated that lesion contrast increased
from 54% at standard dose to 92% at 0.3 mmol/kg. Summarizing
from this and other subsequent work (specifically comparing 0.1 and
0.2 mmol/kg gadobutrol),27 it has been well demonstrated on MR
imaging that a dose of 0.1 mmol/kg does not demonstrate all brain
metastases, in particular smaller lesions.Name Furthest Pursued Development
dofosveset trisodium Clinically approved
docoletic acid trisodium Phase II
U 52 Preclinical
domer-17 Phase II
92 (gadomelitol) Phase I
-2104R Phase II
46 Preclinical
3277 Phase II (in progress)
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 1. Visualization of a brain metastasis with a dose of 0.3 mmol/kg (B, arrow), not detected at 0.1 mmol/kg (A), using a conventional
extracellular, renally excreted, gadolinium chelate, specifically gadoteridol. In this case ofmetastatic lung carcinoma, evaluating the entire examination,
2 metastatic lesions were detected at 0.1 mmol/kg in comparison with 7 at 0.3 mmol/kg. The right frontal metastasis is further confirmed on a
follow-up study (C) performedwith 0.1mmol/kg, whichdemonstrated an increase in lesion size despite interval whole brain radiation therapy. Adapted
with permission.26
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         Earlier work, published from 1987 to 1990,28–30 had already
demonstrated improved enhancement of lesions with higher doses,
the first 2 studies focusing on a dose of 0.2 mmol/kg and the third
encompassing doses from 0.05 to 0.3 mmol/kg. These describe the dose
effect on T1-weighted images, and with it, it is important to consider
also the effect on T2* in first-pass brain studies. Results published in
1990 and 1993,31,32 the earlier being a patient study (evaluating 0.1 and
0.2 mmol/kg) and the latter in experimental animals (evaluating up to
0.5 mmol/kg, in the cat), concluded that the first-pass effect was dose
dependent, with improved efficacy at higher doses.
In 1994, attention was drawn to the need for further studies ad-
dressing the appropriate choice of dose for IV Gd chelate administra-
tion.33 The results of clinical trials at that time suggested improved
efficacy for high-dose contrast administration in multiple organs and
disease states, including specifically the brain, heart, and liver. Animal
studies showed efficacy for doses of 0.5 (cat, brain first pass)32 and 0.6
(rabbit, breath-hold liver imaging) mmol/kg,34 although this work did
not consider the effect of body surface area on dose. Whether animal
imaging studies of contrast dose should be corrected for body surface
area is not clear, although it is classically done for toxicology. It is
also justified in the case of recent nonclinical studies regarding the
question of Gd deposition in the brain after IVGd chelate administrationFIGURE 2. Normal liver enhancement, dynamic temporal time course, from p
normal liver scales with dose up to the highest level evaluated, 0.2 mmol/kg.
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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0.1 mmol Gd/kg in humans).17
Regarding the previously cited work, data for the effect of body
surface area concerning the cat are scarce, whereas a conversion factor
of 3.1 is commonly quoted for the rabbit,35 with the human equivalent
dose in the quoted work thus being 0.2 mmol/kg. For liver evaluation in
humans, there exist phase II data for dynamic scans with gadobenate
dimeglumine, published in 2000 (this was a dose ranging study,
with patients receiving 1 of 4 doses—0.025, 0.05, 0.1, or 0.2 mmol/kg),
which showed a statistically significant improvement in enhancement of
normal liver with higher doses, including specifically the comparison of
0.2 versus 0.1 mmol/kg (Fig. 2).36 A study comparing double-dose
gadobutrol with single-dose gadopentetate dimeglumine later in
2008 confirmed these findings, if the small relaxivity differences be-
tween the agents are disregarded. Specifically, there was an increase
in normal liver signal-to-noise ratio (SNR) with a dose of 0.2 mmol/kg
on dynamic imaging, with the study further demonstrating improved
lesion-liver contrast-to-noise ratio (CNR).37 Cardiac imaging is one
of the few areas that continues to employ routinely a dose higher
than 0.1 mmol/kg of an extracellular, renally excreted Gd chelate.
For visualization and definition of myocardial infarcts on delayed
imaging, a dose of 0.2 mmol/kg is most commonly used today.38 Ithase II clinical evaluation of gadobenate dimeglumine. Enhancement of
Reprinted with permission.36
www.investigativeradiology.com 3
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         should be noted, regardless, that, in some countries (eg, in the United
States), price (and the lack of reimbursement therein) has markedly
restricted the use of doses higher than 0.1 mmol/kg for the Gd che-
lates, particularly in recent years.
Of additional note, most research to date has focused on the eval-
uation of dose in neoplastic disease. Infection is an additional major dis-
ease category, with little data in the literature concerning contrast dose
on MR and detectability therein. For example, it is known that MR is
relatively insensitive for the detection of meningitis. Research using a
dog model of early meningitis in the brain, performed in 1995, demon-
strated improved detectability of meningeal enhancement as contrast
dose was increased.39 Enhancement of meningeal inflammation was
seen with the magnitude therein and the sensitivity of the technique
ranking by contrast dose with 0.8 > 0.3 > 0.1 mmol/kg. Using a conver-
sion factor of 1.8 for the dog (to determine human equivalent doses
on the basis of the body surface area), this equates to evaluation of
0.44 versus 0.17 versus 0.06 mmol/kg. Given that early meningitis is
typically not visualized in patients with a dose of 0.1 mmol/kg, it is
likely that the lowest dose evaluated in these experiments mimics
closely the clinical situation—with only 2 of 5 animals having an ab-
normal postcontrast scan at this dose despite an imaging protocol that
maximized contrast detectability.
The discovery of NSFand subsequently Gd deposition in the brain,
skin, and bone in patients with normal renal function, after administration
of linearGd chelates, has impacted the clinical viewof high dose, evenwith
the macrocyclic agents, owing to the role of dose with the linear agents
in both settings. Unfortunately, use of gadodiamide and gadopentetate
dimeglumine at extremely high doses (up to and exceeding 0.3 mmol/kg)
in renal failure patients in the early days of CE-MRA, and the NSF cases
seen in this group, likely contributed today to this reluctance to inject doses
above 0.1 mmol/kg regardless of agent.40IMAGING TECHNIQUE
Both the time following contrast administration and the specific
pulse technique used for visualization on MR are critical for maximiz-
ing detection of contrast enhancement. However, both factors are often
overlooked. In the very first study demonstrating contrast enhancement
with a Gd chelate in a brain lesion on MR, the existence of a temporal
time course of enhancement was noted, with greater enhancement on
delayed scans.41 This was known from compute tomography and con-
firmed in many subsequent MR studies, including the landmark study
comparing gadopentetate dimeglumine and gadobenate dimeglumine
(with higher relaxivity) for brain lesion enhancement.42 Lesion-to-brain
contrast increases rapidly in the first few minutes after contrast admin-
istration and continues to increase at a slower pace thereafter up to at
least 10 minutes after injection. This factor is often ignored in clinical
practice today with the necessity to complete the examination as rapidly
as possible to ensure high patient throughput. Delayed scans would en-
sure better lesion enhancement in the brain and have been advocated as
a supplement to standard postcontrast scans for improved detection of
brain metastases.43 Alternatively, this result could be achieved by the
use of a next-generation, higher-relaxivity agent. Although the factor
of timing postcontrast for brain lesions has been relatively well studied
(as well as that for the imaging of myocardial scar),44 in other areas of
the body, such as the musculoskeletal system, a temporal time course
likely also exists but has never been evaluated.
The specific pulse sequence and the settings therein are also very
important for visualization of contrast enhancement, with awide variety
of T1-weighted sequences available. For example, at 3 T, if a very rapid
scan of the brain is desired, a 2D short-TE gradient echo sequence can
be used. If high-resolution imaging is desired, the most commonly used
sequence is 3D magnetization prepared rapid gradient-echo, which is
also gradient echo in type. With sequence parameters as commonly
used, unfortunately, gradient echo techniques are inferior to spin echowww.investigativeradiology.com
                                   Copyright © 2018 Wolters Kluwer Health, Inc. Unauth
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For example, a short TE 2D gradient echo technique—which is often
used at 3 T for postcontrast imaging of the brain—is inferior to a 2D
fast spin echo scan, when TE, repetition time, and flip angle are chosen
as commonly used, with voxel size held constant.45 Similarly, for
high-resolution 3D imaging, the most appropriate choice to maximize
visualization of lesion enhancement would be a spin echo–based tech-
nique, such as Sampling Perfection with Application optimized Contrasts
using different flip angle Evolution. The latter, however, is not commonly
used in clinical practice, despite definitive studies demonstrating im-
proved lesion enhancement and detection.46 That Sampling Perfection
with Application optimized Contrasts using different flip angle Evolu-
tion or similar sequences are not used routinely for brain imaging is
likely because of neuroradiologists' preference for a scan with high
gray-white matter contrast, specifically magnetization prepared rapid
gradient-echo. Looking at other areas of the body, little work has ever
been performed to optimize the postcontrast imaging sequence for the
detection of contrast enhancement.
Other approaches have also been studied for maximizing the
detection of a Gd chelate on MR, including specifically the use of
additional radiofrequency pulses. Application of a magnetization
transfer pulse was demonstrated early in the development of clinical MR
to improve the visualization of contrast enhancement in the brain.47,48mag-
netization transfer (MT) pulses suppress the signal intensity of tissue,
thus improving the detectability of contrast enhancement (against a
lower-signal-intensity background). The disadvantages of an MT pulse
include a slight prolongation of imaging time, higher specific absorp-
tion rate, decreased signal intensity from nonenhancing tissue, and an
increase in motion artifacts. MT is rarely used today for postcontrast
imaging, reflecting these factors and in particular the image degradation
from motion. Fluid-attenuated inversion recovery can also be used to
provide improved contrast enhancement in comparison with standard
T1-weighted imaging techniques.49 As with MT, this technique suffers
from accentuatedmotion artifacts, as well as longer scan time and lower
SNR in comparison with conventional techniques. Thus, postcontrast
fluid-attenuated inversion recovery also never achieved widespread
clinical use or acceptance.
Not to be ignored is the impact that personal preference (of the
clinic's radiologist) for imaging sequence, which is highly variable,
has upon everyday clinical practice. A second important factor is the
time constraint (in terms of chosen imaging scans to be run) to achieve
a profit, as opposed to a monetary loss, for the operation of the clinic.
These factors take the choice of imaging technique largely out of the
control of a company attempting to develop a next-generation agent
and could thus negatively affect development and acceptance of such.
Intertwinedwith the choice of pulse sequence (imaging technique),
in terms of influence on the signal intensity produced by a Gd chelate,
is its relaxivity, in vivo concentration, formulated concentration, and
used field strength. Higher T1 relaxivity always comes with higher
T2 relaxivity, the latter also influencing signal intensity. Field strength
strongly influences relaxivity, although the end result in terms of enhance-
ment can be surprising, due to the increase in tissue T1with field strength.INFLUENCING RELAXIVITY
Relaxivities of Current Agents
With the exception of the 2 agents with partial hepatobiliary
excretion (gadoxetate disodium and gadobenate dimeglumine), the T1
relaxivities of the Gd chelates approved worldwide today are closely
clustered. Two major studies have evaluated in vitro T1 relaxivity of
these agents, the first in 2005 at both 1.5 and 3 T, using bovine plasma
and canine whole blood.50 It should be noted that relaxivity can differ
between species, and so these results cannot be completely extrapolated
to humans.51 The second extended these results, reporting relaxivities© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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         at 1.5, 3, and 7 T, and importantly evaluated the agents for the first time
in humanwhole blood.52 At 1.5 T, the range in relaxivities in this group is
from 3.9 to 4.6 s−1 mM−1, and at 3 T, from 3.4 to 4.5. It is to be noted that
for each agent, the specific T1 relaxivity decreases from 1.5 to 3 to 7 T.
However, because the T1 of tissue is prolonged at higher field strengths,
the enhancement effect has been shown to increase from 1.5 to 3 T, de-
spite the decrease in relaxivity.45 From lowest to highest relaxivity, for
all approved agents, the ranking in terms of T1 relaxivity from the
2015 publication of Shen et al (irrespective of field strength) is gadoxet-
ate disodium > gadobenate dimeglumine > the remaining Gd chelates
(gadobutrol, gadodiamide, gadoversetamide, gadoteridol, gadopentetate
dimeglumine, and gadoterate meglumine)—which all have very close,
if not indistinguishable, relaxivities. Although small differences in degree
of lesion enhancement have been shown between agents, for example, in
brain imaging for gadobenate dimeglumine as compared with gadoterate
meglumine (2 agents at the extremes of the range of relaxivities),53 no
agent has ever been approved by either the Food and Drug Administra-
tion or the European Medicines Agency in a half dose (0.05 mmol/kg)
indication (excluding liver imaging), confirming the close clustering of
relaxivities and, thus, enhancement effect of the approved agents.
Blood-Pool Agents
In the history of the development of the Gd chelates, extracellu-
lar agents were first developed, followed by agents with hepatobiliary
excretion. Subsequently, a large effort was expended for the development
of potential blood-pool agents. The first such agent conceptualized was
gadofosveset trisodium8 (also known by its commercial names, Vasovist
and Ablavar). Clinical approval was eventually sought for only 1 agent in
this class, that being gadofosveset trisodium. Today, this agent is no
longer available in either Europe or the United States.
Clinical trials were performed with gadofosveset trisodium
starting the late 1990s54,55 and extending to the following decade. These
trials included evaluation of the carotid arteries, aorta, iliac arteries, and
peripheral vasculature.56–59 Although efficacy was demonstrated, the
potential application of the agent was limited by the concurrent rapid
development of CE-MRA using the extracellular Gd chelates already
clinically available. Contrast-enhanced MRA was first conceptualized
by Revel in the early 1990s.60 Although gadofosveset trisodium offered
the possibility of delayed blood-pool imaging, in addition to first-pass
imaging, this proved not to be of sufficient benefit to keep the agent
on the market. This occurred despite efforts to promote its use, using
the blood-pool features for which the class of agents was developed—
to enable imaging that otherwise might not be possible. For example,
high-resolution delayed imaging was performed in investigation of ath-
erosclerotic disease in both the carotid arteries and lower extremities,
showing improvements relative to first-pass imaging.61,62
Gadofosveset trisodium and other similar agents, for example,
gadocoletic acid trisodium,63 which did not progress to clinical ap-
proval, function by binding to human serum albumin in plasma. This
prolongs the half-life of the agent in the body, retains the agent for at
least some time period within the blood pool, and increases its T1
relaxivity. The latter occurs primarily because of the increase in the ro-
tational correlation time (slower tumbling) when bound to albumin.64
In vitro, in human plasma, the relaxivity of gadofosveset trisodium is
markedly higher than that of the extracellular distributed Gd chelates,
for example, at 0.5 T 53.5 versus 4.7 mmol−1 L s−1 for gadopentetate
dimeglumine.55 However, it should be noted that in vitro measurements
of relaxivity in plasma, at a fixed concentration of Gd, are not necessarily
an accurate reflection of the efficiency of a Gd chelate in vivo, especially
for those molecules that bind to albumin, such as gadofosveset. In vivo,
the proportion of free and bound forms of albumin-binding Gd chelates
varies according to the pharmacokinetic profile, with the relaxivities of
the albumin-bound and the free contrast agent very different (much lower
for the latter). This has led to the concept of “dynamic relaxivity.”65© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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brain tumor enhancement on level of protein binding (Fig. 3).66 Agents
with weak (gadobenate dimeglumine), 50% (BRU 52), and 90%
(B22956/1, gadocoletic acid trisodium) protein binding were compared
with a conventional non–protein-binding extracellular agent, gadopentetate
dimeglumine. Both of the protein-binding agents provided a substantial
improvement in lesion enhancement as compared with the Gd chelates
available clinically today. A major hypothesis of the study was whether
an agent with intermediate protein bindingmight indeed provide substan-
tially greater lesion enhancement than with either stronger or weaker
protein binding. However, both agents with substantial protein binding
(50% vs 90%) proved to have comparable lesion enhancement—by com-
parison to the controls used, in the immediate postinjection timeframe.
Non–protein-binding Gd chelates have also been evaluated as
potential blood-pool agents. Gadomer-17, a paramagnetic complex with
24 Gd atoms bound to a dendrimeric backbone, was developed as a
blood-pool agent and evaluated in the late 1990s and early 2000s. This
compound has a high T1 relaxivity per Gd atom owing to the increase
in rotational correlation time. Because of size, after IV injection, it does
not quickly diffuse into the extravascular space, and although large
enough—to slow this diffusion—it is also small enough to be excreted
by glomerular filtration.67 Although extensively evaluated in animal
studies, only 2 small clinical studies were ever performed.68,69
P792 (gadomelitol) is a large-molecular-weight, high-relaxivity
agent based on a Gd-DOTA skeleton. The hydrodynamic molecular
volume is approximately 125 times that of Gd-DOTA. The increased
molecular weight leads to slowing of the rotational movement and a
marked increase in T1 relaxivity, which at 0.5 T is 39 as compared with
3.5 mmol−1 L s−1 for Gd-DOTA.70 The agent was evaluated in phase I,
in which distribution and clearance were shown to be consistent with a
rapid clearance blood-pool agent.71 One substantial difference between
this type of agent and the albumin binders is that the relaxivity does not
change during the bolus and postbolus timeframes. In the bolus and im-
mediate postbolus phase, the relaxivity of agents that bind to albumin,
for example, gadobenate dimeglumine and gadofosveset, varies. This
occurs because of the change in quantity of bound and free forms.65
InCE-MRA,with the non–protein-binding blood-pool agents, high-quality
early and equilibrium phase MRA images have been demonstrated.72
Fibrin Binding
A single fibrin binding agent, EP-2104R, was developed by EPIX
Pharmaceuticals, Inc subsequent to its initial albumin binding agent,
gadofosveset trisodium.73,74 Although developed as a fibrin specific
agent, EP-2104R is a high-relaxivity agent, in addition to being a tetra-
mer (the peptide at its core is derivatized at both the C- and N-termini
with Gd-DOTA-like moieties). Its relaxivity per Gd ion is roughly twice
that of comparable extracellular Gd chelates (10.5 vs 4.1 mmol−1 L s−1
whenmeasured under similar conditions and 17.4 when bound to fibrin).75
Imaging at 1.5 T, contrast enhancement (as assessed in a brain tumor
model) was demonstrated to bemore than double (Fig. 4), with a prolonged
temporal enhancement course. It is important to note that the increased sig-
nal intensity seen in vivo is likely a result not just of the greater relaxivity
but also of the fibrin binding and thus reduced motion of the molecule.
Utility was demonstrated in swine for targeted imaging of thrombi, specif-
ically in the pulmonary arteries,73 and for coronary thrombosis,76 and as
well for the identification of tumor associated fibrin.77 Before development
was halted, likely on the basis of commercial considerations, at least 1
phase II study was performed,78 demonstrating in man enhancement
and on that basis greater conspicuity of both venous and arterial thrombi.
Non–Protein Binding, Low to Intermediate
Molecular Weight
P846 is an intermediate sized, non–protein binding, macromo-
lecular organic Gd chelate, with approximately half the molecular
weight of P792 (3.5 vs 6.5 kDa). It consists of a single Gd ion withinwww.investigativeradiology.com 5
orized reproduction of this article is prohibited.                                               
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FIGURE 3. Comparison of enhancement with gadolinium chelates differing in the degree of protein binding (rat brain tumor model). In part I,
precontrast images are in the top row, and immediate postcontrast images are in the bottom row. Part I depicts results (presented in the order noted)
with gadopentetate dimeglumine, gadobenate dimeglumine, and B22956/1— the latter a linear gadolinium chelate linked to a deoxycholic acid
derivative, with strong specific protein binding (approximately 90%). Part II provides results with all evaluated agents, including gadopentetate
dimeglumine, gadobenate dimeglumine, B22956/1, and BRU 52—the latter a low-molecular-weight macrocyclic gadolinium chelate with
intermediate protein binding properties (approximately 50%). The contrast dose was 0.1 mmol/kg in all instances. Reprinted with permission.66
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         a macrocyclic 3-armed chelate. As noted with other agents previously
discussed, increasing the molecular weight and volume leads to a reduc-
tion in rotational rate, producing increased time for interaction with wa-
ter protons and higher relaxivity. Unlike P792, P846 is not consideredFIGURE 4. Markedly improved lesion enhancement by the use of a fibrin spe
compared with that using gadopentetate dimeglumine (A) in a rat brain tumo
CNR near double using the fibrin binding agent (despite the use of one-fourth
www.investigativeradiology.com
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                        This paper can be cited using the date of access and the unto be a blood-pool agent, with the intermediate molecular weight
allowing for extravasation and accumulation in tumor tissue. Although
considered a low diffusable agent, there is marked increased crossing of
the disrupted blood-brain barrier with P846 as compared to P792,cific binding gadolinium chelate peptide tetramer (B), with results
r model. Both scans are postcontrast at 5 minutes after injection, with
the dose on a gadolinium ion basis). Reprinted with permission.75
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         likely owing to its smaller size and differences in 3D molecular
structure. In evaluation of a rat brain tumor model, a dose of
0.025 mmol/kg produced comparable lesion enhancement when
compared with a dose of 0.1 mmol/kg of a conventional, clinically
approved, extracellular Gd chelate (Fig. 5).79
P03277 is a low-molecular-weight (0.97 kDa) single Gd-based
contrast agent from Guerbet with a dedicated 3D design to increase
the hydrodynamic size of the complex (patent number EP 1931 673 B1,
page 8, example 2).80 As noted previously, this reduces the molecular
tumbling rate, leading to improved interaction with water protons and
thus increased T1 relaxivity (with R1 at 1.5 T being 12.8 and at 3 T
11.6 mmol−1 L s−1).80 In addition, water access to the Gd ion is im-
proved, with a hydration number of 1.7. The approved conventional
low-molecular-weight complexes of Gd all have a hydration number
of 1. There is no interaction with serum albumin or other plasma
proteins. A phase II study is currently being conducted for central ner-
vous system imaging (ClinicalTrials.gov Identifier: NCT02633501),
looking at lesions with disruption of the blood-brain barrier and evaluating
4 doses—specifically 0.025, 0.05, 0.1, and 0.2mmol/kg in comparison to a
standard dose, 0.1 mmol/kg, of gadobenate dimeglumine. The conven-
tional clinically approved Gd-based agents, as well as the macromolec-
ular contrast agents and the agents with plasma protein interaction, have
a marked deterioration in T1 relaxivity with an increase in field strength
from 1.5 to 3 to 7 T. Although also seen with P03277, it is moderate in
degree, with this agent maintaining notably high T1 relaxivity at
ultrahigh field strengths. Bayer seems also to be in the early stages of
investigating new high-relaxivity extracellular Gd chelates (specifically
agents based on low-molecular-weight core polyamines).81 Bracco is
investigating as well agents within this class (non–protein binding,
low to intermediate molecular weight), introducing recently at a
congress another series of relatively high-relaxivity agents.82
One potential application already cited in the literature would be
the ability to use lower doses of Gd at 1.5 and 3 T. However, any new
Gd agent with higher relaxivity—to receive regulatory approval—
would likely have to deposit an equal or less amount of Gd in the bodyFIGURE 5. Comparison of enhancement with gadolinium chelates differing in
blood-pool agent, specifically a monomeric macromolecular organic gadoliniu
intermediate sized high-relaxivity gadolinium-based contrast agent with rapid
body weight, P792 at 0.05 mmol/kg, and P846 at 0.025 mmol/kg. Adapted w
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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                        This paper can be cited using the date of access and the uncompared with the currently approved macrocycles. Otherwise, there
would be no benefit of going to a lower dose if the amount of Gd depos-
ited is the same or higher than with the macrocyclic agents. Unexplored
is the potential for improved diagnosis both in the brain and in body
imaging due to the enhanced relaxivity with the use of a more con-
ventional dose of 0.1 mmol/kg. Given earlier high-dose studies with
the currently approved conventional Gd chelates, there is great po-
tential in many, if not all, organ systems for the use of an agent like
P03277 at a dose of 0.1 mmol/kg. This is likely even more so the
case given that the selection of standard dose, 0.1 mmol/kg, for the
agents approved today was not made on the basis of efficacy but be-
cause of concerns regarding toxicity, as previously discussed. An ad-
ditional reason for major interest in high-relaxivity contrast agent
without protein binding is that these agents are associated with con-
stant relaxivity. This can open the way to quantitative MR imaging,
specifically with no uncertainty between level of binding and local
contrast agent concentration.
The financial hurdles to industry, however, for the development
of agents within this category (and indeed for any new MR agents) are
substantial. These only start with development costs. Likely far more
challenging will be the level of reimbursement for the cost of a single
dose, in an environment where the payment is already fixed and may
be as well bundled with other costs including the scanner, technologist,
and physician.
Looking more in depth at these obstacles, the following issues
can prevent or deter market access of new, innovative contrast agents.19,83
This can occur even if the compound has excellent proofs of concept and
seems to actually save lives, as was the case with ferumoxtran-10 for
lymph mode imaging in prostate cancer.84 The single use of a contrast
agent for an imaging examination, as compared with, in many cases,
the long-term (months or even years) use of therapeutic agents means that
the financial return for contrast agents is often much smaller. Implemen-
tation of a “first-in-class”MR contrast agent in routine practice is likely
to require the development of dedicated image analysis software and
MR sequences for all types of MR machines, which may impact clinicalmolecular weight (rat brain tumor model). P792 is a high-relaxivity
m chelate, non–albumin binding, with rapid clearance. P846 is an
renal clearance. Gd-DOTA was administered at a dose of 0.1 mmol/kg
ith permission.79
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         development studies and subsequentmarket access. Training of clinicians
and radiographers relative to innovative agents is important and some-
times neglected, even by developers. Particularly from the pharmaceutical
industry's perspective, an important obstacle is the projected volume of
contrast usage. Until a new agent is approved for imaging, its application
can be only off-label, and therewill be the issues of reimbursement, insur-
ance, and the fact that the physicians themselves bear the responsibility
and liability for safety. Contrast agent developers are concerned with
the huge risk of refusal from the health authorities and no obvious guar-
antee that, if marketed, the radiologists will adopt new contrast media. In
the case of a “disruptive” imaging method associated with an innovative
contrast agent, it can be anticipated that a substantial impact to the health
care system will follow (patient flow management, guidelines, training)
that may also impact the use of the new agent and, thus, its chances of
success. Manufacturing issues under good manufacturing practices, for
example, in the case of nanoparticles, is often forgotten in the case of ac-
ademic researchers who launch a new business. Heterogeneity in the use
of contrast agents between countries may depend on the type and nature
of reimbursement. And finally, in the modern health care world, high
pressure on sales prices imposed by payers (for example, governments)
may discourage companies from developing new compounds.
CONCLUSION
In summary, there were limited data from human trials concern-
ing optimum dose before the Gd-based agents were first approved.
Early animal and human investigations support a higher dose (or equiv-
alently higher relaxivity) for improved disease detection and evaluation.
Gadoterate meglumine and gadoteridol remain approved clinically for
up to 0.3 mmol/kg, however, with limited such use.
Next-generation Gd chelates with markedly higher relaxivity
could be realized by improved chelate design, enabling in clinical use
higher SNR and CNR. If used at the doses used today for conventional
agents, improved clinical efficacy would be a likely result, as detailed in
the “Question of Dose” section. Commercial viability could be justified
on the basis of either lowering the Gd ion dose (yet achieving the same
improvement in SNR and CNR) or by keeping dose on this basis con-
stant and improving lesion/tissue enhancement.
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